Puri Michal Nath sold $9K of NVCR

Puri Michal Nath (Chief Human Resources Officer) sold 660 shares of NovoCure Ltd (NVCR) at $13.24 on 2026-11-02.

Original reporting
SEC EDGAR · Puri Michal Nath
Published Nov 4, 2026, 9:05 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Nov 4, 2026, 9:09 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$NVCR
Neutral
high confidence
Mentioned
$NVCR
Relevance
3/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$NVCRNeutralLow
01

Why it matters

The disclosed sale is modest and unlikely to move the stock significantly.

02

Market read

A routine insider sale with limited market impact.

03

What to watch

No change in company fundamentals; the CHRO remains a large shareholder.

Relevance 3/10Novelty 3/10Timing: after market today

Background

SEC Form 4 filing discloses insider transactions for public companies.

Company-level read

Ticker impact

$NVCRNeutralHigh confidence
Context

Form 4 shows CHRO sold 660 shares for $8,738, reducing her stake to 202,567 shares.

Expected impact

likely slight pressure as the market prices in the insider sale

Evidence & confidence

The sale is small relative to total holdings and does not signal material concerns.

Market effects

None

None

None

Counterpoint

The sale could be a routine portfolio rebalancing, not a negative signal.

Key entities

  • NovoCure Ltd

    Biotech firm listed on NASDAQ under ticker NVCR.

  • Puri Michal Nath

    Chief Human Resources Officer of NovoCure.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$NVCRLowAI 8/10

JAMA Network Open Publishes Quality of Life and Pain Outcomes Data from Phase 3 PANOVA-3 Trial of Novocure's Tumor Treating Fields for Pancreatic Cancer

Novocure (NVCR) announced that JAMA Network Open published results from the PANOVA-3 trial of its Tumor Treating Fields (TTFields) therapy for pancreatic cancer. The trial met its primary endpoint, showing improved overall survival. Secondary endpoints also demonstrated significant benefits in pain management and quality of life. TTFields therapy was well-tolerated with no new safety signals. Novocure aims to inform clinicians and patients with these findings.

$NVCRMedAI 8/10

FDA Rejects NovoCure’s Optune Mya for Lung Cancer Brain Metastases. Here's What It Means for Investors.

NovoCure's (NVCR) shares fell 6% after the FDA rejected its Optune Mya device for lung cancer brain metastases, citing uncertainty about clinical benefits. The company plans to meet with FDA officials to discuss a potential approval path. NovoCure's other Optune devices, Gio, Lua, and Pax, are approved and generating revenue, but the company remains unprofitable. The FDA's decision adds to investor concerns about competition from Revolution Medicines' Rasonque pill.

$NVCRHighAI 9/10

Novocure’s device for treating brain metastases rejected by FDA

The FDA rejected Novocure's PMA for Optune Mya, a device for treating brain metastases, citing uncertainty about clinical benefits. The FDA did not raise safety concerns. Novocure plans to discuss feedback with the FDA to explore approval options, but there is no guarantee of future approval. The company has FDA approvals for other TTFields therapies, including Optune Gio, Lua, and Pax.